Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

181.29USD
24 Feb 2017
Change (% chg)

$-4.15 (-2.24%)
Prev Close
$185.44
Open
$182.65
Day's High
$183.86
Day's Low
$180.32
Volume
296,970
Avg. Vol
416,303
52-wk High
$209.20
52-wk Low
$150.14

SHPG.OQ

Chart for SHPG.OQ

About

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $54,627.22
Shares Outstanding(Mil.): 301.57
Dividend: 0.14
Yield (%): 0.44

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 65.66 28.84 29.63
EPS (TTM): 2.76 -- --
ROI: 1.70 13.44 12.96
ROE: 3.11 14.34 14.11

BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab

* No serious adverse events or discontinuations due to adverse events were observed at all doses studied

Feb 23 2017

UPDATE 2-China updates key drug list in boost for Big Pharma

* GSK, AZ, Shire welcome update (Adds GSK statement, analyst comment, details)

Feb 23 2017

Pharma group Shire produces top-of-the-range earnings

LONDON Pharmaceuticals group Shire on Thursday said it was extremely optimistic about long-term growth after reporting a 12 percent rise in earnings for the past year in which it made its largest ever acquisition.

Feb 16 2017

UPDATE 1-Pharma group Shire produces top-of-the-range earnings

* Shares rise 6 pct (Adds CEO comments, analyst reaction, shares)

Feb 16 2017

Pharma group Shire posts earnings rise at top of guidance

LONDON, Feb 16 Pharmaceuticals group Shire reported a 12 percent rise in full-year earnings after what it said was a transformational year marked by its largest acquisition to date, adding that it is extremely optimistic on long-term growth prospects.

Feb 16 2017

Federal Circuit clears proposed generic version of Shire's Lialda

A federal appeals court has removed a roadblock to the launch of a generic version of Shire PLC's bowel disease drug Lialda, reversing a lower court decision that the generic version would infringe Shire's patent.

Feb 13 2017

UPDATE 2-FTC sues Shire ViroPharma for fighting generic entry of Vancocin

WASHINGTON, Feb 7 The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of hijacking a government channel designed to flag safety issues by using it to fend off generic competition, the agency said in a statement.

Feb 07 2017

FTC sues Shire ViroPharma for fighting generic entry of Vancocin

WASHINGTON The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of abusing government processes in order to fend off generic competition to its antibiotic Vancocin HCl, the agency said in a statement.

Feb 07 2017

FTC sues Shire ViroPharma for fighting generic entry of Vancocin

WASHINGTON, Feb 7 The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of abusing government processes in order to fend off generic competition to its antibiotic Vancocin HCI, the agency said in a statement.

Feb 07 2017

BRIEF-U.S FDA acknowledges receipt of Shire's ADHD drug application

* U.S. FDA acknowledges receipt of Shire's new drug application for SHP465 for ADHD

Jan 19 2017

More From Around the Web

Earnings vs. Estimates